The closing price of Intellia Therapeutics Inc (NASDAQ: NTLA) was $26.83 for the day, down -0.30% from the previous closing price of $26.91. In other words, the price has decreased by -$0.08 from its previous closing price. On the day, 729314 shares were traded.
Ratios:
Our analysis of NTLA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.67 and its Current Ratio is at 8.67. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 23, 2024, Downgraded its rating to Neutral and sets its target price to $32 from $136 previously.
On April 13, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $66.Canaccord Genuity initiated its Buy rating on April 13, 2023, with a $66 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’24 when BASTA JAMES sold 2,297 shares for $32.99 per share. The transaction valued at 75,778 led to the insider holds 81,571 shares of the business.
Clark Eliana sold 605 shares of NTLA for $19,959 on Mar 04 ’24. The EVP, Chief Technical Officer now owns 71,470 shares after completing the transaction at $32.99 per share. On Jan 08 ’24, another insider, Sepp-Lorenzino Laura, who serves as the EVP, Chief Scientific Officer of the company, sold 2,275 shares for $28.87 each. As a result, the insider received 65,682 and left with 43,927 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 2.59B and an Enterprise Value of 1.79B. For the stock, the TTM Price-to-Sale (P/S) ratio is 71.10 while its Price-to-Book (P/B) ratio in mrq is 2.38. Its current Enterprise Value per Revenue stands at 49.33 whereas that against EBITDA is -3.53.
Stock Price History:
Over the past 52 weeks, NTLA has reached a high of $47.48, while it has fallen to a 52-week low of $22.67. The 50-Day Moving Average of the stock is 27.60, while the 200-Day Moving Average is calculated to be 32.86.
Shares Statistics:
NTLA traded an average of 1.60M shares per day over the past three months and 1.39M shares per day over the past ten days. A total of 96.11M shares are outstanding, with a floating share count of 93.89M. Insiders hold about 2.30% of the company’s shares, while institutions hold 85.61% stake in the company. Shares short for NTLA as of Feb 29, 2024 were 12.62M with a Short Ratio of 7.89, compared to 10.97M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.13% and a Short% of Float of 14.71%.
Earnings Estimates
The firm’s stock currently is rated by 22 analysts. On average, analysts expect EPS of -$1.38 for the current quarter, with a high estimate of -$1.02 and a low estimate of -$1.58, while EPS last year was -$1.17. The consensus estimate for the next quarter is -$1.29, with high estimates of -$0.98 and low estimates of -$1.68.
Analysts are recommending an EPS of between -$4.55 and -$7.07 for the fiscal current year, implying an average EPS of -$5.61. EPS for the following year is -$5.49, with 25 analysts recommending between -$1.72 and -$7.59.
Revenue Estimates
A total of 26 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $102.5M, while the lowest revenue estimate was $9M, resulting in an average revenue estimate of $50.72M. In the same quarter a year ago, actual revenue was $36.27M, up 39.80% from the average estimate.
